Newly developed retatrutide, a twin -action drug targeting simultaneously GLP-1 and GIP receptors, is generating considerable excitement within the healthcare community. Preliminary clinical studies have demonstrated significant reductions in body mass and gains in metabolic markers for people with overweight. Researchers believe this unique appro